See more : CHAR Technologies Ltd. (YES.V) Income Statement Analysis – Financial Results
Complete financial analysis of 23andMe Holding Co. (MEUSW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 23andMe Holding Co., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- XCana Petroleum Corporation (XCPT) Income Statement Analysis – Financial Results
- Clarity Pharmaceuticals Ltd (CU6.AX) Income Statement Analysis – Financial Results
- Shirai Electronics Industrial Co., Ltd. (6658.T) Income Statement Analysis – Financial Results
- Nick Scali Limited (NCK.AX) Income Statement Analysis – Financial Results
- Polyard Petroleum International Group Limited (8011.HK) Income Statement Analysis – Financial Results
23andMe Holding Co. (MEUSW)
About 23andMe Holding Co.
23andMe, Inc., a consumer genetics and research company, engages in developing a genetic database to unlock insights leading to the rapid discovery of new targets for drug development. It offers a crowdsourced platform that helps people to access, understand, and benefit from the human genome; access direct-to-consumer genetic testing; and give consumers personalized information about their genetic health risks, ancestry, and traits. The company was incorporated in 2006 and is based in Sunnyvale, California with an additional office in Mountain View, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 219.64M | 299.49M | 271.89M | 243.92M | 305.46M | 440.90M |
| Cost of Revenue | 120.26M | 164.99M | 138.95M | 126.91M | 168.03M | 257.91M |
| Gross Profit | 99.38M | 134.50M | 132.95M | 117.01M | 137.43M | 182.99M |
| Gross Profit Ratio | 45.25% | 44.91% | 48.90% | 47.97% | 44.99% | 41.50% |
| Research & Development | 205.36M | 222.60M | 189.38M | 159.86M | 181.28M | 140.53M |
| General & Administrative | 148.33M | 115.98M | 97.38M | 99.15M | 59.39M | 50.29M |
| Selling & Marketing | 85.60M | 119.93M | 100.34M | 43.20M | 110.52M | 190.85M |
| SG&A | 205.74M | 235.91M | 197.72M | 142.35M | 169.91M | 231.24M |
| Other Expenses | 9.63M | -93.00K | -83.00K | 1.32M | 1.34M | 0.00 |
| Operating Expenses | 420.73M | 458.51M | 387.10M | 302.20M | 351.19M | 371.77M |
| Cost & Expenses | 540.99M | 623.50M | 526.05M | 429.12M | 519.22M | 629.68M |
| Interest Income | 14.33M | 9.68M | 277.00K | 1.58M | 6.24M | 5.25M |
| Interest Expense | 0.00 | 0.00 | 277.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.48M | 36.50M | 26.15M | 20.25M | 22.25M | 9.90M |
| EBITDA | -291.87M | -291.94M | -228.01M | -164.95M | -191.51M | -173.63M |
| EBITDA Ratio | -132.89% | -96.00% | -95.99% | -67.62% | -47.72% | -40.57% |
| Operating Income | -321.36M | -324.01M | -254.15M | -185.20M | -213.76M | -188.78M |
| Operating Income Ratio | -146.31% | -108.19% | -93.48% | -75.92% | -69.98% | -42.82% |
| Total Other Income/Expenses | -345.28M | 9.58M | 33.18M | 1.58M | -37.11M | 5.25M |
| Income Before Tax | -666.63M | -314.43M | -220.97M | -183.62M | -250.86M | -183.53M |
| Income Before Tax Ratio | -303.51% | -104.99% | -81.27% | -75.28% | -82.13% | -41.63% |
| Income Tax Expense | 73.00K | -2.77M | -3.48M | -255.00K | 38.45M | 9.74M |
| Net Income | -666.70M | -311.66M | -217.49M | -183.36M | -289.31M | -183.53M |
| Net Income Ratio | -303.55% | -104.06% | -79.99% | -75.17% | -94.71% | -41.63% |
| EPS | -1.40 | -13.81 | -9.96 | -9.04 | -12.34 | -9.03 |
| EPS Diluted | -28.01 | -13.81 | -9.96 | -9.04 | -12.34 | -9.03 |
| Weighted Avg Shares Out | 475.98M | 22.58M | 21.83M | 20.32M | 20.32M | 20.32M |
| Weighted Avg Shares Out (Dil) | 23.80M | 22.58M | 21.83M | 20.32M | 20.32M | 20.32M |
Source: https://incomestatements.info
Category: Stock Reports